Bionano Genomics effects 1-for-10 reverse stock split, effective August 4, 2023

Bionano Genomics, Inc.

Reverse stock split at ratio 1:10 effective 5:00 p.m. ET on August 4, 2023; trading on split-adjusted basis begins August 7, 2023.
No fractional shares issued; stockholders otherwise entitled to fractional share receive cash in lieu.
Proportionate adjustments to per-share exercise price and shares of stock options, RSUs, and warrants.
Certificate of Elimination filed for Series A Preferred Stock (no shares outstanding), removing designation from charter.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bionano Genomics, Inc.: Amended certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2023-08-04).

Change: charter amendment
Effective: 2023-08-04

Exact text from the filing

On August 4, 2023, Bionano Genomics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “ Restated Certificate ”), with the office of the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:10 (the “ Charter Amendment ”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bionano Genomics, Inc.: Filed certificate of elimination to remove designation of Series A Preferred Stock and restore it to undesignated authorized preferred shares (effective 2023-08-04).

Change: charter amendment
Effective: 2023-08-04

Exact text from the filing

On August 4, 2023, prior to the Company’s filing of the Charter Amendment with the office of the Secretary of State of the State of Delaware, the Company filed a Certificate of Elimination (the “ Certificate of Elimination ”) with the office of the Secretary of State of the State of Delaware with respect to the Company’s Series A Preferred Stock, par value $0.0001 per share (the “ Series A Preferred Stock ”), following the automatic redemption of all outstanding shares of Series A Preferred Stock after the conclusion of the 2023 Annual Meeting.

View on SEC.gov

29 governance changes filed in the last 30 days. Browse all governance changes →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-038095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.